» Authors » Ivan Guerra

Ivan Guerra

Explore the profile of Ivan Guerra including associated specialties, affiliations and a list of published articles. Areas
Snapshot
Articles 60
Citations 459
Followers 0
Related Specialties
Top 10 Co-Authors
Published In
Affiliations
Soon will be listed here.
Recent Articles
1.
Calafat M, Suria C, Mesonero F, de Francisco R, Yague Caballero C, de la Pena L, et al.
Am J Gastroenterol . 2025 Jan; 120(2):431-439. PMID: 39888687
Introduction: The coexistence of HIV infection and inflammatory bowel disease (IBD) is uncommon. Data on the impact of HIV on IBD course and its management are scarce. The aim of...
2.
Gisbert J, Donday M, Riestra S, Lucendo A, Benitez J, Navarro-Llavat M, et al.
Gut . 2025 Jan; 74(3):387-396. PMID: 39794921
Background And Objectives: Primary objectives: to compare the rates of sustained clinical remission at 12 months in patients treated with antitumour necrosis factor (anti-TNF) and immunomodulators who withdraw anti-TNF treatment...
3.
Aguas M, Del Hoyo J, Vicente R, Barreiro-de Acosta M, Melcarne L, Hernandez-Camba A, et al.
J Med Internet Res . 2024 Aug; 26:e60966. PMID: 39189160
Background: Telemonitoring for inflammatory bowel disease (IBD) has not consistently demonstrated superiority over standard care; however, noninferiority may be an acceptable outcome if remote care proves to be more efficient....
4.
Sanz Segura P, Gomollon F, Casas D, Iborra M, Vela M, Fernandez-Clotet A, et al.
Dig Liver Dis . 2024 Jun; 56(12):2060-2068. PMID: 38876834
Background: some patients with inflammatory bowel disease (IBD) treated with antiTNF develop drug-induced psoriasis (antiTNF-IP). Several therapeutic strategies are possible. Aims: to assess the management of antiTNF-IP in IBD, and...
5.
Guerra I, Barros F, Chaparro M, Benitez J, Martin-Arranz M, de Francisco R, et al.
Dig Dis . 2024 Mar; 42(3):257-264. PMID: 38452742
Introduction: Risk factors for developing pancreatitis due to thiopurines in patients with inflammatory bowel disease (IBD) are not clearly identified. Our aim was to evaluate the predictive pharmacogenetic risk of...
6.
Rubin de Celix C, Martin-de-Carpi J, Pujol-Muncunill G, Palomino L, Rodriguez-Belvis M, Martin-Masot R, et al.
J Clin Med . 2023 Jul; 12(14). PMID: 37510928
(1) Background: Transition is a planned movement of paediatric patients to adult healthcare systems, and its implementation is not yet established in all inflammatory bowel disease (IBD) units. The aim...
7.
Guerra I, Bujanda L, Manosa M, Perez-Martinez I, Casanova M, de la Pena L, et al.
Cancers (Basel) . 2023 Feb; 15(3). PMID: 36765708
An increased risk of lymphoma has been described in patients with inflammatory bowel disease (IBD). The aims of our study were to determine the clinical presentation, the previous exposure to...
8.
Zabana Y, Marin-Jimenez I, Rodriguez-Lago I, Vera I, Martin-Arranz M, Guerra I, et al.
J Clin Med . 2022 Dec; 11(24). PMID: 36556155
(1) Scant information is available concerning the characteristics that may favour the acquisition of COVID-19 in patients with inflammatory bowel disease (IBD). Therefore, the aim of this study was to...
9.
Algaba A, Romero S, Granja A, Garza D, Aller M, Barrero S, et al.
Gastroenterol Hepatol . 2022 May; 46(1):48-53. PMID: 35605819
Objective: To study the serological response (SR) and tolerability of COVID-19 vaccine in patients with inflammatory bowel disease (IBD) and its relation with IBD treatment and type of vaccine. Methods:...
10.
Guijarro L, Cano-Martinez D, Toledo-Lobo M, Ruiz-Llorente L, Chaparro M, Guerra I, et al.
Biomedicines . 2022 Mar; 10(3). PMID: 35327530
Background: Recently, increased tissue levels of AIF-1 have been shown in experimental colitis, supporting its role in intestinal inflammation. Therefore, we studied the levels of AIF-1 in Crohn’s disease (CD)....